SCHEMBL16748876

SCHEMBL16748876

Cc1ncc(COc2cc(F)cc(Oc3ccc(B4OC(C)(C)C(C)(C)O4)cc3)c2)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 2/20 0.39
▸ LPL P06858 6/20 0.38
▸ LIPG Q9Y5X9 6/20 0.38
▸ SNCA P37840 1/20 0.36
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA9 Q16790 1/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ HIF1A Q16665 2/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ CXCR2 P25025 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16748845 0.83 DGAT1 (0.44) DGAT1LPLLIPGSNCACA1
SCHEMBL16748875 0.81 CYP1A2 (0.51) L3MBTL1LMNAPOLBRAB9AATM
SCHEMBL13860126 0.78 LPL (0.56) DGAT1LPLLIPGSNCACA1
SCHEMBL15607533 0.72 L3MBTL1 (0.40) CA1CA9L3MBTL1LMNAPOLB
SCHEMBL368960 0.71 LPL (0.71) LPLLIPGSNCACA1CA2
SCHEMBL15615024 0.71 L3MBTL1 (0.37) L3MBTL1LMNAPOLBRAB9AATM
SCHEMBL16886116 0.69 L3MBTL1 (0.39) L3MBTL1LMNAPOLBRAB9AATM
SCHEMBL29719698 0.69 LIPG (0.51) LPLLIPGSNCACA1CA2
SCHEMBL13860162 0.69 LIPG (0.51) LPLLIPGSNCACA1CA2
SCHEMBL5243207 0.69 CA1 (0.61) DGAT1LPLLIPGSNCACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822120-B2 Protein kinase inhibitors PHARMASCIENCE INC. (CA) 2017-11-21 — — US disclosed
US-9822120-B2 Protein kinase inhibitors PHARMASCIENCE INC. (CA) 2017-11-21 — — US disclosed
US-20160280711-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2016-09-29 — — US disclosed
US-20160280711-A1 Protein Kinase Inhibitors PHARMASCIENCE INC. (CA) 2016-09-29 — — US disclosed
WO-2015074138-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE INC. (CA) 2015-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280711-A1 Protein Kinase Inhibitors TEC, LCK, SRC DGAT1 3167/4885LPL 4292/4885LIPG 2806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback